High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Open Access
- 9 April 2013
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 161 (5), 695-700
- https://doi.org/10.1111/bjh.12338
Abstract
Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide. Here, we studied CRBN expression by real time polymerase chain reaction in 49 bone marrow samples of newly diagnosed patients with multiple myeloma treated with lenalidomide and dexamethasone. Median CRBN expression was 3·45 in patients who achieved complete response, and 3·75, 2·01, 0·78, and 0·70 in those with very good partial response, partial response, stable disease and progressive disease respectively. CRBN expression levels correlated significantly with response to lenalidomide treatment (r = 0·48; P < 0·001). Among established prognostic parameters, only beta‐2‐microglobulin correlated with cereblon (r = 0·66; P < 0·001). A close association of CRBN with interferon regulatory factor 4 (IRF4) (P < 0·001) and with CTNNB1 (P < 0·001) was found. Overall, a statistically significant association between baseline CRBN expression and response in MM patients treated with lenalidomide is shown. CRBN expression is closely associated with IRF4, which is an important target of IMiD therapy.Keywords
This publication has 23 references indexed in Scilit:
- Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to LenalidomideJournal of Biological Chemistry, 2011
- Teratogenic effects of thalidomide: molecular mechanismsCellular and Molecular Life Sciences, 2011
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia, 2009
- Lenalidomide: a novel anticancer drug with multiple modalitiesExpert Opinion on Pharmacotherapy, 2008
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myelomaLeukemia, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and DifferencesSeminars in Hematology, 2005
- High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemiaLeukemia, 2004